Many initiatives have tried to address this partnership challenge: the Healthcare Communications Association’s (HCA) own ...

Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s ...

Women have played a crucial role in rare disease awareness and better care, overcoming gender biases and systemic challenges ...

Bristol Myers Squibb (BMS) has announced positive results from a phase 3b/4 study of its oral TYK2 inhibitor Sotyktu ...

Medscape wants to take the opportunity to look back and recap what was accomplished at ESC 2024. At this year’s event, ...

Eli Lilly has announced that it is investing $4.5bn into a new US facility for advanced manufacturing and drug development. The Lilly Medicine Foundry will give the company the ability to research new ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD). The ...

The fourth annual QiC Dermatology Awards took place in Reading earlier this month and results can be found online here: QiC Dermatology 2024 Results – Quality in Care Awards Programme. NHS teams from ...

Johnson & Johnson’s (J&J) Yuvanci (single tablet combination therapy [STCT] of macitentan and tadalafi) has been approved by the European Commission (EC) as a long-term treatment for pulmonary ...

From travel planning to DIY, and everything in between, when we need information or an answer to any problem, our instinct is to grab our nearest device and search online, whether through Google, ‘X’ ...

UCB has shared positive two-year results for its inflammatory disease drug Bimzelx (bimekizumab) in moderate-to-severe hidradenitis suppurativa (HS). New data from the phase 3 BE HEARD I and BE HEARD ...

AstraZeneca’s (AZ) Tagrisso (osimertinib) has been approved by the US Food and Drug Administration (FDA) to treat a new subset of lung cancer patients. The epidermal growth factor receptor ...